Issue Date: June 7, 2004
Millennium gets Corey chemistry
Millennium Pharmaceuticals has signed a research agreement with Harvard University and Harvard chemistry professor E. J. Corey. Under the deal, Harvard has granted Millennium rights to intellectual property for a family of proteasome inhibitors made with a chemical synthesis developed by Corey. Millennium will pay milestone fees and royalties to Harvard on sales of products resulting from the deal. Millennium won approval for the first proteasome-inhibiting drug, the blood cancer treatment Velcade (bortezomib), about a year ago.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society